The ratio of the inhibitor concentration to the inhibition constant (K i ) is used as the index for predicting drug-drug interactions involving metabolic inhibition. The maximum unbound concentration in the circulation (I p,max,u ) and the maximum unbound concentration at the inlet to the liver (I u,max ) have been used for the inhibitor concentration. In the present study, the methods for predicting drug-drug interactions using these concentrations were evaluated by Monte Carlo simulation. Information on the pharmacokinetic parameters of drugs and the K i values for cytochrome P450(CYP) were obtained from the literature. It was assumed that the pharmacokinetic parameters (intrinsic metabolic clearance, renal clearance and distribution volume for unbound fraction), serum protein binding and K i value for substrate and inhibitor are all log-normally distributed. Correlations among the parameters were assessed and were used for further simulations. A change in AUC of the substrate following co-administration of the inhibitor was simulated 1000 times using the physiologically based pharmacokinetic (PBPK) model. The percent of the drug combinations which exhibited a signiˆcant increase in the AUC (À125z) was 16.2z of the total combinations. The cases where the I W K i using I u,max and I p,max,u overestimated compared with the actual increased ratio of AUC (false positive prediction) were 41.2z and 16.7z, respectively. The cases where the predicted ratios of AUC from I W K i using I u,max and I p,max,u were comparable with the actual ratio were 3.2z and 8.7z, respectively. The prediction using I p,max,u was, thus, more reliable than that using I u,max . However, in the case of I u,max , there was no case where the actual increased ratio of AUC was greater than that predicted from I W K i (false negative prediction). On the other hand, for I p,max,u , the rate of false negative prediction was 1.4z. The present study indicates that I u,max is better than I p,max,u for avoiding false negative predictions and I p,max,u is better than I u,max for increasing the probability of true positive and true negative predictions and avoiding false positive predictions.
Introduction
Many cases of adverse reactions caused by clinically relevant drug-drug interactions have been reported. It is important to be able to predict such drug-drug interactions because, especially in the case of drugs with a narrow therapeutic index, critical adverse reactions can be caused by only a slight increase in plasma concentration following administration of a combination of drugs. [1] [2] [3] [4] [5] [6] [7] Metabolic inhibition can involve both reversible and irreversible inhibition. Reversible inhibition can involve competitive, and non-competitive inhibition, and the prediction of reversible inhibition is easy compared with irreversible inhibition. In the case of a competitive and noncompetitive inhibition of drug metabolism, when the substrate concentration is su‹ciently lower than the Km, the rate of metabolism of a substrate in the presence of an inhibitor reduces to 1 W (1＋I W Ki) of that without an inhibitor, where I and Ki are the inhibitor concentration and inhibition constant, respectively. 8, 9) Therefore, when the inhibitor concentration is constant, one can predict that the AUC increases by a factor of 1＋I W Ki. Since human microsomes or human CYP expression systems have become more readily available for in vitro studies, it is now possible to evaluate the Ki for human CYPs. It has been reported that Iu W Ki is useful as an index for predicting drug-drug interactions.
1-3)
However, it is not yet agreed which concentration should be used. It has been reported that a false negative prediction sometimes takes place when the maximum unbound concentration in the circulating blood (Ip,max,u) is used as the inhibitor concentration. 1, 10) We have proposed that the maximum unbound concentration at the inlet to the liver (Iu,max) should be used to avoid false negative predictions. 1, 10) However, the prediction methods for drug-drug interactions using Iu,max and Ip,max,u have not been compared in detail. The prediction methods for drug-drug interactions using Iu,max and Ip,max,u have been assessed by Monte Carlo simulation where the plasma concentration-time proˆles of a substrate after oral administration of a substrate alone and co-administration with a inhibitor were simulated by a PBPK model using randomly generated pharmacokinetic parameters.
Methods
Obtaining pharmacokinetic parameters: The pharmacokinetic parameters of 181 drugs were obtained from Goodman and Gilman's textbook, The Pharmacological Basis of Therapeutics, 9th ed.
11) The Ki values of drugs for CYPs using human microsomes or recombinant CYP isozymes reported by Ito et al. 10) were used. The distribution volume (Vd) and renal clearance (CLr) were divided by the plasma unbound fraction (fp). The hepatic clearance (CLh) and intrinsic clearance (CLint) were estimated from the total body clearance (CL t ) and CLr using the following equations.
CLh＝CLt-CLr
CLint＝QhCLh W (Qh-CLh) W fb where CL t , Q h and f b are the total body clearance, hepatic blood ‰ow rate and blood unbound fraction, respectively. Qh and Rb (blood-to-plasma concentration ratio) were assumed to be 1610 mL W min and 1, respectively. nPt W Kd was calculated as nPt W Kd＝(1-fp) W fp. nPt and K d are the total protein concentration and dissociation constant for plasma protein binding, respectively. Theˆrst order absorption rate constants from gut (ka) of 27 drugs were calculated from the time to reach the maximum concentration (Tmax) using the following equation.
where ke is the elimination rate constant from plasma. The statistical parameters, mean, standard deviation (SD), kurtosis and skewness, were calculated to evaluate the distribution of the pharmacokinetic parameters. The correlation coe‹cients among the diŠerent pharmacokinetic parameters were calculated.
Simulation: The PBPK model of substrate and inhibitor is shown in Fig. 1 . The distribution of all parameters of substrate and inhibitor was assumed to be log-normal. The pharmacokinetic parameters were generated as random numbers, taking the correlations among the parameters into consideration. The plasma concentration-time proˆles of a substrate after oral administration of substrate alone and co-administration with an inhibitor were simulated using the following diŠerential equations by the Runge-Kutta-Gill method up to the time to reach 1 W 100 of the maximum concentration. The calculation interval was 0.05 min. The simulation was performed by the program described above with visual basic in Excel 2000 (Microsoft Corporation).
where Csys, Cliver, Cpv, CLint,s, CLnh, Fa,s, ka,s, Vsys,s, Kp,s and f u,s are the blood concentration, concentration in liver, concentration in portal vein, hepatic intrinsic clearance, extrahepatic clearance, fraction absorbed, rst-order absorption rate constant from gut, systematic distribution volume, ratio of liver to blood concentra- tion and unbound fraction in blood for substrate, respectively, and Isys, Iliver, Ipv, CLint,i, CLnh,i, Fa,i, ka,i, Vsys,i, Kp,i, fu,i and Ki are the blood concentration, concentration in liver, concentration in portal vein, hepatic intrinsic clearance, extrahepatic clearance, fraction absorbed,ˆrst-order absorption rate constant from gut, systematic distribution volume, ratio of liver to blood concentration, unbound fraction in blood and inhibition constant for inhibitor, respectively and Vpv is the volume of the portal vein. Q h is the sum of the blood ‰ow in the hepatic artery and portal vein. Fa,s ,Fa,i, Kp,s and Kp,i were assumed to be 1. An important index (I W Ki) for predicting drug-drug interactions was estimated using Iu,max, Ip,max,u and Ip,max as the I value. Ip,max is the maximum concentration in the systemic circulation. Iu,max can be calculated as follows 1, 10) :
where k a is theˆrst-order absorption rate constant from the gut, Fa is the fraction absorbed from the gut into the portal vein. The degree of interaction was shown as the increased ratio of AUC. The increase in AUC was subdivided into seven stages as shown in Table 3 . The case where I W K i was less than 0.25 and the increased ratio of AUC was less than 125z was considered as a true negative prediction. The case where the increased ratio of AUC was greater than that predicted from I W Ki was considered as a false negative prediction. The case where The correlation coe‹cients among pharamacokinetic parameters are shown in Table 2 .
the I W Ki overestimated two or more stages greater than that corresponding to the actual increased ratio of AUC was considered as a false positive prediction. The case where the I W Ki was the same as or overestimated one stage greater than that corresponding to the actual increased ratio of AUC was considered as a true positive prediction.
Results
Distribution of PK parameters: Figure 2 and Table 1 show the distribution and statistical values of logarithm-transformed pharmacokinetic parameters for the drugs. The kurtosis and skewness of these parameters were less than 1.5 except for the dose. Then, the distribution of all parameters was assumed to be log-normally distributed. The correlations among parameters are shown in Fig. 3 and Table 2 . A signiˆcant correlation (│r│À0.396) was observed among Vd W fp, nPt W kd, CLint and Ki. CLr W fp was signiˆcantly correlated with CLint. Although the dose was signiˆcant-ly correlated with nPt W Kd and Vd W fp, the correlation coe‹cients were low, being -0.372 and -0.320, respectively. Since a signiˆcant correlation among some parameters was observed, the pharmacokinetic parameters were randomly generated taking these correlations into consideration.
Monte Carlo simulation: Table 3 shows the relationship between inhibitor concentration (I u,max , Ip,max,u and Ip,max) W Ki ratio and the degree of in vivo interaction obtained by Monte Carlo simulation. The increased ratio of AUC was less than 125z for 83.8z of the total combinations while the increased ratio of AUC was more than 200z for 5.4z. In the case of predictions using Iu,max, no false negative predictions were observed. On the other hand, for predictions using Ip,max,u, 8.6z (14 W 162) of the cases where AUC increased by 125z were false negatives. False negative predictions using I p,max were also observed and this involved 3.7z (6 W 162) of the cases where the AUC increased by 125z. The frequency of false negative, false positive, true negative, and true positive predictions using Iu,max, Ip,max,u and Ip,max is shown in Table 4 . The rate of false positive predictions using I u,max and I p,max,u was 41.2z and 16.7z, respectively. The rate of true positive and true negative predictions using Iu,max was 3.2z and 55.6z, respectively and the rates using Ip,max,u were 8.7z and 73.2z, respectively. The prediction using I p,max,u was, thus, more reliable than that using I u,max .
Discussion
The pharmacokinetic parameters of drugs were collected to evaluate the method of predicting drug-drug interactions by Monte Carlo simulation. All parameters except the dose were log-normally distributed. The mean value of CLr W fp for drugs was close to the glomerularˆltration rate. This coincidence is considered to be due to the fact that secretion and re-absorption were balanced. There was a signiˆcant correlation among nPt W Kd, Clint and Vd W fp. (Table 2 ) Considering that these parameters have been correlated with lipophilicity, [12] [13] [14] [15] these correlations among such parameters might be due to the correlation between lipophilicity and these parameters. The Ki value for CYPs had a negative correlation with nPt W Kd, CLint and Vd W fp. This correlation might be due to the more lipophilic drugs being able to reach the P-450 in microsomes. 14) A change in the AUC of a substrate following co-administration of inhibitor was simulated 1000 times by the PBPK model. These 1000 simulations resulted in 14 false negative predictions and may be a su‹cient number of simulations to evaluate the prediction methods. The rate at which the AUC increased more than 125z, i.e. the criteria for a signiˆcant drug-drug interaction iǹ`M ethods of Drug interaction Studies'' from the Ministry of Health, Labor and Welfare in Japan, 16) was 16z of the total combinations under such conditions ( Table 3) . In only 5.4z of cases did the AUC increase by 200z (Table 3 ). In the present study, it was assumed that a substrate is absorbed completely and metabolized via a single pathway. It is expected that the actual degree of interaction becomes smaller than the degree obtained by simulation because many drugs are metabolized by multiple metabolic and elimination pathways and some drug are not absorbed completely. On the other hand, the parameters were randomly produced based on the information on the compounds which are already used, as mentioned above. It is necessary to interpret any result by taking into consideration the fact that the compounds which we have selected in the present simulations may have better pharmacokinetic characteristics than those in the discovery and development stages. Therefore, when we deal with drug candidates, it is easy to imagine that there will be an increased probability of interactions. The result of the prediction method using Iu,max and Ip,max,u obtained by this Monte Carlo simulation is summarized (Table 3 and 4) . The frequency of false positive predictions using Iu,max was greater than that using Ip,max,u (42z vs 17z). This result will not change, even if the criteria for true positive predictions become more strict. The true positive and true negative predictions using Iu,max were 3z and 56z, respectively while the true positive and true negative predictions using Ip,max,u were 9z and 73z, respectively. The prediction using I p,max,u was superior to the prediction using Iu,max. The outstanding advantage of prediction using Iu,max is that it completely avoids false negative predictions ( Table 3) . On the other hand, in the case of the prediction using Ip,max,u, 8.6z (14 W 162) of the cases where the AUC increased 125z were false negatives. In the prediction using the total concentration in the blood circulation, the probability of true positive and true negative predictions was as low as that using Iu,max. Furthermore, there can also be a problem involving some false negative predictions and, so, that method cannot be recommended. Prediction using Iu,max is made under an unlikely assumption, namely, that the inhibitor concentration at the inlet to the liver following absorption from the intestine and the concentration in the systemic circulation reach a maximum concentration simultaneously. Therefore, it is easy to understand why this method is associated with a high probability of false positive predictions. On the other hand, the method using Ip,max,u does not take into consideration the inhibitor concentration absorbed from the intestine. Therefore, it is understandable that this method is associated with false negative predictions. So, from the aboveˆnd-ings, the method using Iu,max is recommended to avoid false negative predictions and the method using Ip,max,u is also recommended to avoid false positive predictions. These methods should be used in conjunction according to the stage of drug development. We would like to propose the following methods. (1) In the early discovery stage (where there are many candidates): compounds should be rejected if they cause an interaction and compounds which do not cause an interaction should be selected. When an interaction by a candidate is ruled out by the method using Iu,max and the other pharmacokinetic and pharmacodynamic characteristics of a candidate are excellent, that candidate should be chosen for further development. On the other hand, when a severe interaction by a candidate is predicted using Ip,max,u, unless its other pharmacokinetic and pharmacodynamic characteristics are excellent, it should be rejected. The basic idea behind our proposal is to use I u,max when choosing a candidate and Ip,max,u when rejecting it. However, during the early discovery stage, there should be no overemphasis on choosing a candidate based on the results of the prediction of interactions using Ip,max W Ki or Iu,max W Ki as well as the metabolic stability, protein binding, absorption and other pharmacological investigations. (2) In the late discovery stage (ˆnal selection of a clinical candidate), the probability of predicting an interaction needs to be very high. Both simple methods using Iu,max and I p,max,u cannot produce su‹ciently precise predictions since both methods do not use the plasma concentration-time proˆles of the substrate and inhibitor. In order toˆnally choose the compound(s) which should go into clinical trials, when predicting an interaction, prediction based on the PBPK model shown Fig. 1 is required. The pharmacokinetic parameters of a candidate can be obtained from the results of in vitro investigations using human tissue fractions or animal models. [17] [18] [19] A major problem which needs to be solved in future involves the intestinal interactions associated with thê rst-pass eŠect. In the case of compounds which are substrates of CYP3A4 W P-gp, this prediction is of critical importance. So far, the prediction of such interactions has not been successful because it is di‹cult to estimate the eŠective concentrations of substrate and inhibitor in the intestine. This will become an important research topic in the near future. When a candidate is an inhibitor of CYP3A4 and an interaction is predicted, the actual increase in AUC may be greater than that predicted since there may be a contribution from the intestinal interaction.
